Is Ancient Medical Treatment an Option for Curating Osteosarcoma Combined with Chemotherapy? A Basic Analysis of Clinic Pharmacy
- 1 September 2024
- journal article
- research article
- Published by Bentham Science Publishers Ltd. in Combinatorial Chemistry & High Throughput Screening
- Vol. 27 (15) , 2267-2277
Abstract
Background:: As a malignant tumor, osteosarcoma (OS) ranks first place among adolescent cancers and is susceptible to developing resistance to chemotherapeutic agents. Differently, traditional Chinese medicine (TCM) has multiple pharmacodynamic targets and complex biological components, which can inhibit tumor survival and drug resistance and gradually play an important role in the treatment of sarcoma. Methods:: This study is to systematically evaluate the safety and efficacy of TCM combined with chemotherapy performed in the clinical treatment of OS. Based on multiple mainstream databases, eleven articles on the relationship between natural products and chemotherapy involving 656 patients were selected from all the literature published as of June 2022. Revman 5.4 software was used for a comprehensive search analysis, supplemented by established exclusion criteria, the Jadad scale, and the evaluation methods provided by Cochrane. Results:: The efficiency of TCM combined with chemotherapy was significantly increased compared with chemical drugs alone [OR=2.56, 95% CI (1.36,4.79), Z=2.92, P=0.003]. Meanwhile, the adverse reactions such as nausea and vomiting, hepatotoxicity, and hematological changes caused by chemical drugs were alleviated correspondingly. Conclusion:: This study indicates that the mode of TCM combined with chemotherapy sheds light on the clinical treatment of OS, which is much better than the one-way mode.Keywords
Funding Information
- Dalian Life and Health Guidance Plan Project (2022YG014)
- Basic Research Funds for Central Universities (DUT22YG239)
- Liaoning Provincial Natural Science Fund (2021-MS-121)
- Jilin Provincial Development and Reform Commission Industrial Technology Research and Development Project (2020C033-6)
This publication has 23 references indexed in Scilit:
- The Hippo in the room: Targeting the Hippo signalling pathway for osteosarcoma therapiesJournal of Cellular Physiology, 2020
- Exopolysaccharides from a Codonopsis pilosula endophyte activate macrophages and inhibit cancer cell proliferation and migrationThoracic Cancer, 2018
- Cancer stem cells in osteosarcomaCancer Letters, 2017
- Advances in Bone‐targeted Drug Delivery Systems for Neoadjuvant Chemotherapy for OsteosarcomaOrthopaedic Surgery, 2016
- Osteosarcoma: Current Treatment and a Collaborative Pathway to SuccessJournal of Clinical Oncology, 2015
- Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled TrialJournal of Clinical Oncology, 2015
- External application of traditional Chinese medicine in the treatment of bone cancer pain: a meta-analysisSupportive Care in Cancer, 2015
- Chemotherapy for osteosarcoma – Where does it come from? What is it? Where is it going?Expert Opinion on Pharmacotherapy, 2013
- Hepatoprotective activities of a sesquiterpene-rich fraction from the aerial part of Cichorium glandulosumChinese Medicine, 2012
- OsteosarcomaAnnals of Oncology, 2010